Connect Biopharma Holdings Limited Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Connect Biopharma Holdings Limited share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- Connect Biopharma Holdings Limited share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 131.50K shares, a 4283.50% increase year-over-year.
- Connect Biopharma Holdings Limited share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 548.53K shares.
- Connect Biopharma Holdings Limited share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 206.29K shares.
- Connect Biopharma Holdings Limited share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 781.32K shares, a 287.91% increase from fiscal 2024.
- Connect Biopharma Holdings Limited share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 201.42K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | 886.33K shares derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | 131.50K shares 10-Q · filed 2026-05-12 | 909.83K shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | 548.53K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | 781.32K shares 10-K · filed 2026-03-31 |
| 2025-09-30 | 206.29K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | |
| 2025-06-30 | 23.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | |
| 2025-03-31 | 3.00K shares 10-Q · filed 2025-05-15 | |
| 2024-12-31 | 201.42K shares 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |